Ph.D. D.K. Myloslavsky

Government Institution «L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

The review of literature from foreign and native sources provides historical data on the mechanisms of blood pressure regulation through the prism of millennia, the main stages of the evolution of views on the term «hypertensive disease», its main theories and clinical and pathogenetic forms, modifiable risk factors and individual pathogenetic links of disease, primarily disorders in the renin-angiotensin and sympatho-adrenal systems, the hemodynamic factor, immune and genetic mechanisms, well-known luminaries in the field of hypertension are mentioned, attention on the Kharkiv therapeutic school and academician Malaya L.T. in the study of this pathology is focused, therapeutic approaches to the correction of essential hypertension in the historical aspect in detail are discussed, and also taking into account modern Іnternational and Ukrainian recommendations for the diagnosis, treatment and prevention of this category of patients

Key words: hypertension, historical data, mechanisms of blood pressure regulation, renin-angiotensin and sympatho-adrenal systems, hemodynamic factor, immune and genetic mechanisms, luminaries in the field of hypertension, Kharkiv therapeutic school, treatment approaches.

https://doi.org/10.15407/internalmed2025.02.054

Download.PDF(ukr)

References:

1. Miasnikov AL, editor. Gipertonicheskaia bolezn \[Hypertensive disease\]. Moscow: Medgiz; 1960. 204 p. (Russian).

2. Dziak HV, Vasylieva LI. Arterialna hipertenziia. Suchasni uiavlennia pro patohenez i likuvannia \[Arterial hypertension. Modern views on pathogenesis and treatment\]. Dnipropetrovsk; 1998. 151 p. (Ukrainian).

3. Kovalenko VN, Talaieva TV, Bratus VV. Serdechno-sosudistye zabolevaniia i renin-anhioetenzinovaia sistema \[Cardiovascular diseases and the renin-angiotensin system\]. Kyiv: Morion; 2013. 232 p. (Russian).

4. Koval SM, Snihurska IO, Mysnychenko OV, Penkova MIu. Arterialna hipertenziia u viiskovosluzhbovtsiv ta veteraniv riznykh viin. Ohliad literatury \[Arterial hypertension in servicemen and veterans of various wars. Literature review\]. Ukrainskyi terapevtychnyi zhurnal. 2023;(1):44-50. (Ukrainian).

5. Koval SM, Snihurska IO. Stres-indukovana arterialna hipertenziia ta arterialna hipertenziia viiskovoho chasu – hrizni vyklyky suchasnii Ukraini \[Stress-induced arterial hypertension and wartime arterial hypertension – formidable challenges to modern Ukraine\]. Arterialnaia gipertenziia. 2015;(5):13-8. (Ukrainian).

6. Koval SN, Starchenko TH, Iushko KA. Rol apelina v razvitii serdechno-sosudistoi patologii \[The role of apelin in the development of cardiovascular pathology\]. Ukrainskii terapevticheskii zhurnal. 2013;(2):94-100. (Russian).

7. Korotkov NS. K voprosu o sposobakh izmereniia krovianogo davleniia (iz kliniki S. P. Fedorova) \[On the question of methods for measuring blood pressure (from the clinic of S. P. Fedorov)\]. Izvestiia Imperatorskoi Voenno-meditsinskoi akademii SPb. 1905;11:365-7. (Russian). https://doi.org/10.17816/rmmar692969

8. Kushakovskii MS. Gipertonicheskaia bolezn \[Hypertensive disease\]. Saint Petersburg: Sotis; 1995. 311 p. (Russian).

9. Mala LT, Koval SM, Bilovil OM, Myloslavskyi DK. Farmakolohichni vlastyvosti ta terapevtycne znachennia ingibitoriv anhiotenzin-peretvoriuichoho fermentu v kardiolohii \[Pharmacological properties and therapeutic significance of angiotensin-converting enzyme inhibitors in cardiology\]. Kharkiv; 1999. 50 p. (Ukrainian).

10. Malaia LT, Koval SN, Ivanov EN, Hryhorova IA, Myloslavskyi DK. HLA-antigeny u bolnykh gipertonicheskoi bolezn’iu \[HLA antigens in patients with hypertensive disease\]. Zhurnal NAMN Ukrainy. 1997;(1):112-7. (Russian).

11. Malaia LT, Mikliaev IIu, Kravchun PG. Mikrotsirkuliatsiia v kardiologii \[Microcirculation in cardiology\]. Kharkov: Vyshcha shkola; 1977. 231 p. (Russian).

12. Malaia LT, Berkelieva SCh, Berkeliev MB. Neirogumoralnye sistemy v patogeneze, diagnostike i lechenii gipertonicheskoi bolezni \[Neurohumoral systems in the pathogenesis, diagnosis and treatment of hypertensive disease\]. Ashgabat: Ylym; 1993. 261 p. (Russian).

13. Melnyk VV, Kryvetskyi VV, Proniaiev DV, Yemelianenko NR, Voloshyn VL, Kuchuk OP. Istoriia rozvytku vchennia pro imunnu systemu \[History of the development of the doctrine of the immune system\]. Bukovynskyi medychnyi visnyk. 2023;27(3):115-21. doi: 10.24061/2413-0737.27.3.107.2023.19. (Ukrainian). https://doi.org/10.24061/2413-0737.27.3.107.2023.19

14. Miloslavskyi DK. Evoliutsiia vzgliadov na mekhanizmy reguliatsii arterialnogo davleniia i patogeneticheskie faktory vozniknoveniia gipertonicheskoi bolezni \[Evolution of views on the mechanisms of blood pressure regulation and pathogenetic factors of the onset of hypertensive disease\]. Ukrainskii terapevticheskii zhurnal. 2015;(4):78-88. (Russian).

15. Miasnikov AL. Gipertonicheskaia bolezn i ateroskleroz \[Hypertensive disease and atherosclerosis\]. Moscow: Meditsina; 1965. 615 p. (Russian).

16. Ministerstvo okhorony zdorovia Ukrainy. Pro zatverdzhennia Unifikovanoho klinichnoho protokolu pervynnoi ta spetsializovanoi medychnoi dopomohy «Hipertonichna khvoroba (arterialna hipertenziia)» \[On the approval of the Unified Clinical Protocol for Primary and Specialized Medical Care “Hypertensive disease (arterial hypertension)”\]. Nakaz MOZ Ukrainy vid 12.09.2024 № 1581. Available from: https://umj.com.ua/uk/novyna-257868-zatverdzheno-klinichnij-protokol-gipertonichna-hvoroba-arterialna-gipertenziya. (Ukrainian).

17. Syrenko YuN. Gipertonicheskaia bolezn i arterialnye gipertenzii \[Hypertensive disease and arterial hypertension\]. Donetsk: Izdatel Zaslavskii AYu; 2011. 288 p. (Russian).

18. Uchenie o gipertonicheskoi bolezni – glavnyi vklad GF Langa v razvitie kardiologii \[The doctrine of hypertensive disease – G.F. Lang’s main contribution to the development of cardiology\]. Arterialnaia gipertenziia. 2007;13(1):84-6. (Russian).

19. A brief history of hypertension. Johns Hopkins Med Lett Health After 50. 1999;11(6):7.

20. Abegaz SB. Human ABO Blood Groups and Their Associations with Different Diseases. Biomed Res Int. 2021;2021:6629060. doi: 10.1155/2021/6629060. https://doi.org/10.1155/2021/6629060

21. Acheson GH. Tetraethylammonium, ganglionic blocking agents, and the development of antihypertensive therapy. Perspect Biol Med. 1975;19(1):136-48. doi: 10.1353/pbm.1975.0050. https://doi.org/10.1353/pbm.1975.0050

22. Agrest A. \[The renin saga\]. Medicina (B Aires). 2000;60(1):37-45. (Spanish).

23. Alstad KS. Effect of thiocyanate on basal blood pressure. Br Med J. 1948;1(4544):250. doi: 10.1136/bmj.1.4544.250. https://doi.org/10.1136/bmj.1.4544.250

24. Aoki K. Short history of epidemiology for noninfectious diseases in Japan. Part 2: epidemiology of stroke and hypertension up to 1970. J Epidemiol. 2008;18(1):2-18. doi: 10.2188/jea.18.2. https://doi.org/10.2188/jea.18.2

25. Backer M. Essential hypertension; the birth of its concept two hundred years ago. Angiology. 1953;4(3):207-9. doi: 10.1177/000331975300400303. https://doi.org/10.1177/000331975300400303

26. Bakris GL, Weber MA. Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today. Hypertension. 2024;81(4):717-26. doi: 10.1161/HYPERTENSIONAHA.124.21953. https://doi.org/10.1161/HYPERTENSIONAHA.124.21953

27. Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019;74(6):1232-65. doi: 10.1161/HYPERTENSIONAHA.119.12105. https://doi.org/10.1161/HYPERTENSIONAHA.119.12105

28. Beamish RE, Adamson JD. Treatment of Essential Hypertension with Sodium Thiocyanate. Can Med Assoc J. 1945;53(3):236-42.

29. Bezerra TTD, Bezerra LS, Santos-Veloso MAO, Lordsleem ABMDS, Lima SG. Association between hyperuricemia and hypertension: a case-control study. Rev Assoc Med Bras (1992). 2021;67(6):828-32. doi: 10.1590/1806-9282.20210021. https://doi.org/10.1590/1806-9282.20210021

30. Bishop T, Figueredo VM. Hypertensive therapy: attacking the renin-angiotensin system. West J Med. 2001;175(2):119-24. doi: 10.1136/ewjm.175.2.119. https://doi.org/10.1136/ewjm.175.2.119

31. Boura AL. History of research into hypertension. J R Soc Med. 1992;85(8):509.

32. Braun-Menendez E, Fasciolo JC, Leloir LF, Muñoz JM. The substance causing renal hypertension. J Physiol. 1940;98(3):283-98. doi: 10.1113/jphysiol. 1940.sp003850. https://doi.org/10.1113/jphysiol.1940.sp003850

33. Calvo-Vargas CG. \[A centennial of two great discoveries in the history of medicine: hyperpiesis and the sphygmomanometer (1896-1996)\]. Gac Med Mex. 1996;132(5):529-34. (Spanish).

34. Cameron JS. The description of essential hypertension by Frederick Akhbar Mahomed. Nephrol Dial Transplant. 1995;10(7):1244-7. https://doi.org/10.1093/ndt/10.7.1244

35. Cherne PN, Young P. \[History of the renin-angiotensin system: great men, a great finding\]. Rev Med Chil. 2014;142(9):1210-6. doi: 10.4067/S0034-98872014000900017. (Spanish). https://doi.org/10.4067/S0034-98872014000900017

36. Coy VJ. Genetics of essential hypertension. Am Acad Nurse Pract. 2005;17(6):219-24. doi: 10.1111/j.1041-2972.2005.00036.x. https://doi.org/10.1111/j.1041-2972.2005.00036.x

37. Cui H, Wang YM, Kuang YZ. \[Association between essential hypertension and immunology\]. Zhonghua Nei Ke Za Zhi. 1992;31(1):21-3, 60. (Chinese).

38. Dosne Pasqualini C. \[Juan Carlos Fasciolo, disciple of Houssay and discoverer of angiotensin\]. Medicina (B Aires). 2011;71(4):405-7. (Spanish).

39. Dupont AG. The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years. Cardiovasc Drugs Ther. 1993;7(Suppl 1):55-62. doi: 10.1007/BF00877958. https://doi.org/10.1007/BF00877958

40. Emtiazy M, Choopani R, Khodadoost M, Tansaz M, Dehghan S, Ghahremani Z. Avicenna’s doctrine about arterial hypertension. Acta Med Hist Adriat. 2014;12(1):157-62.

41. Esler M. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension. Exp Physiol. 2011;96(7):611-22. doi: 10.1113/expphysiol.2010.052332. https://doi.org/10.1113/expphysiol.2010.052332

42. Estes EH, Kerivan LJ. An archaeologic dig: a rice-fruit diet reverses ECG changes in hypertension. J Electrocardiol. 2014;47(5):599-607. doi: 10.1016/j.jelectrocard.2014.05.008. https://doi.org/10.1016/j.jelectrocard.2014.05.008

43. Esunge PM. From blood pressure to hypertension: the history of research. J R Soc Med. 1991;84(10):621. doi: 10.1177/014107689108401019. https://doi.org/10.1177/014107689108401019

44. Ferro CJ, Steeds RP, Townend JN. Hypertension, arterial haemodynamics and left ventricular disease: historical observations. QJM. 2012;105(7):709-16. doi: 10.1093/qjmed/hcs059. https://doi.org/10.1093/qjmed/hcs059

45. Franceschini N, Reiner AP, Heiss G. Recent findings in the genetics of blood pressure and hypertension traits. Am J Hypertens. 2011;24(4):392-400. doi: 10.1038/ajh.2010.218. https://doi.org/10.1038/ajh.2010.218

46. Freis ED. Reminiscences of the Veterans Administration trial of the treatment of hypertension. Hypertension. 1990;16(4):472-5. doi: 10.1161/01.hyp.16.4.472. https://doi.org/10.1161/01.HYP.16.4.472

47. Frohlich ED. The first Irvine H. Page lecture. The mosaic of hypertension: past, present and future. J Hypertens Suppl. 1988;6(4):S2-11. doi: 10.1097/00004872-198812040-00002. https://doi.org/10.1097/00004872-198812040-00002

48. Garay-Gutiérrez NF, Hernandez-Fuentes CP, García-Rivas G, Lavandero S, Guerrero-Beltrán CE. Vaccines against components of the renin-angiotensin system. Heart Fail Rev. 2021;26(3):711-26. doi: 10.1007/s10741-020-10033-1. https://doi.org/10.1007/s10741-020-10033-1

49. Gorzkowski E. \[Pavlov’s teaching and hypertension\]. Pol Tyg Lek (Wars). 1951;6(49-50):1583-8. (Polish).

50. Grassi G. Thirty-five years of the European Society of Hypertension: from past to future. J Hypertens. 2024;42(9):1516-20. doi: 10.1097/HJH.0000000000003778. https://doi.org/10.1097/HJH.0000000000003778

51. Gulak PV, Orlov SN. Yuvenali V. Postnov: in celebration of his 75th birthday. J Hypertens. 2004;22(5):1045-6. doi: 10.1097/00004872-200405000-00029. https://doi.org/10.1097/00004872-200405000-00029

52. Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol. 2003;24(1):27-39. doi: 10.1385/MB:24:1:27. https://doi.org/10.1385/MB:24:1:27

53. Hamdy RC. Hypertension: a turning point in the history of medicine…and mankind. South Med J. 2001;94(11):1045-7. doi: 10.1097/00007611-200111000-00001. https://doi.org/10.1097/00007611-200111000-00001

54. Hanefeld M, Schaper F, Ceriello A. \[History and definition(s) of metabolic syndrome\]. Internist (Berl). 2007;48(2):117-25. doi: 10.1007/s00108-006-1786-5. (German). https://doi.org/10.1007/s00108-006-1786-5

55. Hart JT. Historical footnote on the treatment of mild hypertension. BMJ. 2012;345:e6297. doi: 10.1136/bmj.e6297. https://doi.org/10.1136/bmj.e6297

56. Hasani D, Bahrami M, Ahanghar H, Kamalinejad M, Faghihzadeh S, Dadmehr M. A Review on the Hypotheses about Arterial Hypertension from the Viewpoint of Traditional Persian Medicine. Galen Med J. 2020;9:e1065. doi: 10.31661/gmj.v9i0.1065. https://doi.org/10.31661/gmj.v9i0.1065

57. Hypertension as an expression of the lack of the well-balanced life. JAMA. 2014;311(5):530. doi: 10.1001/jama.2013.279313. https://doi.org/10.1001/jama.2013.279313

58. Ishizu T, Seo Y, Kameda Y, et al. Left ventricular strain and transmural distribution of structural remodeling in hypertensive heart disease. Hypertension. 2014;63(3):500-6. https://doi.org/10.1161/HYPERTENSIONAHA.113.02149

59. Jones DW, Ferdinand KC, Taler SJ, Johnson HM, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025 Aug 14. doi: 10.1161/HYP.0000000000000249. https://doi.org/10.1161/HYP.0000000000000249

60. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications. Hypertension. 2010;56(1):10-6. doi: 10.1161/HYPERTENSIONAHA.109.140186. https://doi.org/10.1161/HYPERTENSIONAHA.109.140186

61. Kalehoff JP, Oparil S. The Story of the Silent Killer: A History of Hypertension: Its Discovery, Diagnosis, Treatment, and Debates. Curr Hypertens Rep. 2020;22(9):72. doi: 10.1007/s11906-020-01077-7. https://doi.org/10.1007/s11906-020-01077-7

62. Kamrani Rad SZ, Javadi B, Hayes AW, KarimI G. Potential angiotensin converting enzyme (ACE) inhibitors from Iranian traditional plants described by Avicenna’s Canon of Medicine. Avicenna J Phytomed. 2019;9(4):291-309.

63. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. 1970. JAMA. 1996;276(15):1269-78. https://doi.org/10.1001/jama.1996.03540150071040

64. Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 2024;47(5):1099-1102. doi:10.1038/s41440-024-01622-w. https://doi.org/10.1038/s41440-024-01622-w

65. Kempner W. Treatment of hypertensive vascular disease with rice diet. Arch Intern Med. 1974;133(5):758-90. https://doi.org/10.1001/archinte.1974.00320170040005

66. Korotkov NS. Concerning the problem of the methods of blood pressure measurement. J Hypertens. 2005;23(1):5. doi: 10.1097/00004872-200501000-00003. https://doi.org/10.1097/00004872-200501000-00003

67. Kreutz R. Professor Giuseppe Mancia receives the Excellence Research Award of the Council on Hypertension of the American Heart Association. Blood Press. 2020;29(6):338. doi: 10.1080/08037051.2020.1839221. https://doi.org/10.1080/08037051.2020.1839221

68. Kulkarni S, Wilkinson IB. Adrenoceptors and Hypertension. Handb Exp Pharmacol. 2024;285:297-332. doi: 10.1007/164_2024_719. https://doi.org/10.1007/164_2024_719

69. Kuschnir MC, Mendonça GA. Risk factors associated with arterial hypertension in adolescents. Pediatr (Rio J). 2007;83(4):335-42. doi: 10.2223/JPED.1647. https://doi.org/10.2223/JPED.1647

70. Laragh J. Harry Goldblatt 1891-1977. Trans Assoc Am Physicians. 1978;91:24-7.

71. Laragh JH. Concept of anti-renin system therapy. Historic perspective. Am J Med. 1984;77(2A):1-6. doi: 10.1016/s0002-9343(84)80051-0. https://doi.org/10.1016/S0002-9343(84)80051-0

72. Lemmer B. White coat hypertension: described more than 250 years ago. Am J Hypertens. 1995;8(4 Pt 1):437-8.

73. Mallion JM. \[This is the year of the centenary of arterial hypertension\]. Arch Mal Coeur Vaiss. 1996;89(8):961. (French).

74. Maloney WJ, Resillez-Urioste F, Maloney M. The hypertension of president Franklin Roosevelt. The president as casualty of war. N Y State Dent J. 2012;78(6):37-40.

75. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804-14. doi: 10.1161/CIRCRESAHA.114.302524. https://doi.org/10.1161/CIRCRESAHA.114.302524

76. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. https://doi.org/10.1097/HJH.0000000000003480

77. Mancia G, Magrini F, Morganti A, Stella A, et al. In Memoriam: Alberto Zanchetti (Parma July 27, 1926 – Milan March 24, 2018). J Clin Hypertens (Greenwich). 2018;20(5):826-8. doi: 10.1111/jch.13315. https://doi.org/10.1111/jch.13315

78. Mancia G, Zanchetti A. One hundred years of auscultatory blood pressure: commemorating N. S. Korotkoff. J Hypertens. 2005;23(1):1-2. doi: 10.1097/00004872-200501000-00001. https://doi.org/10.1097/00004872-200501000-00001

79. Messerli FH. This day 50 years ago. N Engl J Med. 1995;332(15):1038-9. doi: 10.1056/NEJM199504133321518. https://doi.org/10.1056/NEJM199504133321518

80. Michel JB. \[William Harvey reinterpreted in the light of species evolution (II) – Physiological and pathological consequences of the evolution of circulation\]. Med Sci (Paris). 2020;36(11):1004-11. doi: 10.1051/medsci/2020171. (French). https://doi.org/10.1051/medsci/2020171

81. Middeke M. The pioneer in hemodynamics and pulse-wave analysis, Otto Frank. J Am Soc Hypertens. 2016;10(4):290-6. doi: 10.1016/j.jash.2016.01.022. https://doi.org/10.1016/j.jash.2016.01.022

82. Milei J. A cornerstone in the history of hypertension: the seventieth anniversary of the discovery of angiotensin. J Cardiovasc Med (Hagerstown). 2010;11(4):260-4. doi: 10.2459/JCM.0b013e3283356607. https://doi.org/10.2459/JCM.0b013e3283356607

83. Milei J. The discovery of angiotensin: a foundational step in the history of hypertension. Physiological Mini Reviews (PMR). 2021;14(Special Issue):2-11.

84. Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich). 2006;8(8 Suppl 2):15-20; quiz 39. doi: 10.1111/j.1524-6175.2006.05836.x. https://doi.org/10.1111/j.1524-6175.2006.05836.x

85. Moser M. Salute to the icons of hypertension. J Clin Hypertens (Greenwich). 2004;6(1):8-9. doi: 10.1111/j.1524-6175.2004.02871.x. https://doi.org/10.1111/j.1524-6175.2004.02871.x

86. Mukharliamov NM, Borodulin VI. \[A. L. Miasnikov and his school\]. Ter Arkh. 1973;45(12):21-9. (Russian).

87. Mukhin NA, Moiseev SV, Fomin VV. \[Evolution of the ideas about arterial hypertension in the papers of E.M. Tareev\]. Ter Arkh. 2006;78(12):9-15. (Russian).

88. Nicolaysen G, Iversen PO. \[Salt and hypertension – 100 years of unresolved issues\]. Tidsskr Nor Laegeforen. 2004;124(24):3191-3. (Norwegian).

89. Nikula TD, Shchulipenko IM, Konopleva LF, Karpenko VV. \[The problems of arterial hypertension in the works of the scientists of the Kiev Medical Institute (on the 150th anniversary of the Institute) (a review of the literature)\]. Vrach Delo. 1991;(2):113-8. (Russian).

90. Nilsson H, Lundgren O. Björn Folkow (1921-2012). Acta Physiol (Oxf). 2012;206(4):251-4. doi: 10.1111/apha.12031. https://doi.org/10.1111/apha.12031

91. Nilsson P, Werkö L. \[Swedish research in hypertension\]. Sven Med Tidskr. 2001;5(1):61-74. (Swedish).

92. Nucklos R, Shapiro JI. Arthur Guyton, sodium, and hypertension. Biol Res Nurs. 2003;5(2):77-8. doi: 10.1177/1099800403258347. https://doi.org/10.1177/1099800403258347

93. O’Brien E. End of the Joint National Committee heritage? Hypertension. 2014;63(5):904-6. doi: 10.1161/HYPERTENSIONAHA.113.03097. https://doi.org/10.1161/HYPERTENSIONAHA.113.03097

94. O’Rourke MF, O’Brien C, Edelman ER. Arterial Stiffening in Perspective: Advances in Physical and Physiological Science Over Centuries. Am J Hypertens. 2016;29(7):785-91. doi: 10.1093/ajh/hpw019. https://doi.org/10.1093/ajh/hpw019

95. Page IH. Arterial hypertension. 1942. Conn Med. 1992;56(8):455-6.

96. Peet MM, Isberg EM. The surgical treatment of essential hypertension. J Am Med Assoc. 1946;130:467-73. doi: 10.1001/jama.1946.02870080001001. https://doi.org/10.1001/jama.1946.02870080001001

97. Pickering T. Ambulatory blood pressure monitoring: an historical perspective. Clin Cardiol. 1992;15(5 Suppl 2):II3-5. doi: 10.1002/clc.4960151403. https://doi.org/10.1002/clc.4960151403

98. Pickering TG. The history and politics of salt. J Clin Hypertens (Greenwich). 2002;4(3):226-8. doi: 10.1111/j.1524-6175.2002.01091.x. https://doi.org/10.1111/j.1524-6175.2002.01091.x

99. Poselyugina OB, Volkov VS, Al-Galban N. \[Hypertension and table salt consumption: a view of the problem 60 years after the publication of G. F. Lang’s monograph “Hypertensive disease”\]. Klin Med (Mosk). 2012;90(10):74-6. (Russian).

100. Prichard BN. The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future. 1978. Br J Clin Pharmacol. 2004;58(7):S807-27; discussion S828-30. doi: 10.1111/j.1365-2125.2004.02302.x. https://doi.org/10.1111/j.1365-2125.2004.02302.x

101. Prochnau D, Figulla HR, Surber R. Renal denervation in the treatment of drug-resistant hypertension: current knowledge and future perspectives. Expert Rev Med Devices. 2013;10(2):247-56. doi: 10.1586/erd.13.1. https://doi.org/10.1586/erd.13.1

102. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition. 1997;13(1):65; discussion 64, 66. doi: 10.1016/s0899-9007(96)00380-2. https://doi.org/10.1016/S0899-9007(96)00380-2

103. Roguin A. Scipione Riva-Rocci and the men behind the mercury sphygmomanometer. Int J Clin Pract. 2006;60(1):73-9. doi: 10.1111/j.1742-1241.2005.00548.x. https://doi.org/10.1111/j.1742-1241.2005.00548.x

104. Rojas E, Rodríguez-Molina D, Bolli P, et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep. 2014;16(8):463. https://doi.org/10.1007/s11906-014-0463-7

105. Rossier BC. \[History of salt\]. Rev Med Suisse Romande. 1998;118(3):285-93. (French).

106. Rump LC. \[Hypertension–what has changed since Moliere and Hemingway?\]. Dtsch Med Wochenschr. 2007;132(46):2429. doi: 10.1055/s-2007-991667. (German). https://doi.org/10.1055/s-2007-991667

107. Sabbadin C, Calò LA, Armanini D. The story of spironolactones from 1957 to now: from sodium balance to inflammation. G Ital Nefrol. 2016;33(Suppl 66):33. S66.12.

108. Santhanam P, Masannat Y. Body mass index, mortality, and the obesity paradox in type 2 diabetes mellitus: the effect of hypertension. South Med J. 2014;107(6):361. doi: 10.14423/01.SMJ.0000450710.46174.e2. https://doi.org/10.14423/01.SMJ.0000450710.46174.e2

109. Santoro D, Bellinghieri G, Savica V, Gembillo G. Franz Volhard: 150th Birth Anniversary of a Father of Nephrology and Hypertension. Exp Clin Transplant. 2023;21(Suppl 2):38-41. doi: 10.6002/ect.IAHNCongress.09. https://doi.org/10.6002/ect.IAHNCongress.09

110. Säwe U. From smoking behaviour to nicotine addiction: the history of research. J R Soc Med. 1992;85(3):184.

111. Schadewaldt H. \[History of hypertension\]. Med Welt. 1984;35(1-2):114-23. (German). https://doi.org/10.1093/gh/1.1.35

112. Sealey JE. John H. Laragh, MD: clinician-scientist. Am J Hypertens. 2014;27(8):1019-23. doi: 10.1093/ajh/hpu110. https://doi.org/10.1093/ajh/hpu110

113. Sen S. The context: investigation into hypertension and cardiac hypertrophy. Cardiovasc Res. 2000;45(1):63-7. doi: 10.1016/s0008-6363(99)00297-7. https://doi.org/10.1016/S0008-6363(99)00297-7

114. Smithwick RH. The surgical physiology of hypertension. Surg Clin North Am. 1949;29(6):1699-1730. doi: 10.1016/S0039-6109(16)32883-3. https://doi.org/10.1016/S0039-6109(16)32883-3

115. Stergiou GS, Parati G, McManus RJ, Head GA, Myers MG, Whelton PK. Guidelines for blood pressure measurement: development over 30 years. J Clin Hypertens (Greenwich). 2018;20(7):1089-91. doi: 10.1111/jch.13295. https://doi.org/10.1111/jch.13295

116. Tracy RE. History, the kidney, and hypertension in blacks versus whites. Am J Hypertens. 2000;13(9):1049-50. doi: 10.1016/s0895-7061(00)00258-2. https://doi.org/10.1016/S0895-7061(00)00258-2

117. Tsao CW, Vasan RS. The Framingham Heart Study: past, present and future. Int J Epidemiol. 2015;44(6):1763-6. doi: 10.1093/ije/dyv336. https://doi.org/10.1093/ije/dyv336

118. Uri K, Fagyas M, Mányiné Siket I, et al. New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure. PLoS One. 2014;9(4):e87845. doi: 10.1371/journal.pone.0087845. https://doi.org/10.1371/journal.pone.0087845

119. van Gijn J, Gijselhart JP. \[Riva-Rocci and blood pressure\]. Ned Tijdschr Geneeskd. 2013;157(3):A5536. (Dutch).

120. van Zwieten PA, Farsang C. Combination of antihypertensive drugs from a historical perspective. Blood Press. 2005;14(2):72-9. doi: 10.1080/08037050510008922. https://doi.org/10.1080/08037050510008922

121. Victor Dzau MD. Eur Heart J. 2016;37(34):2618-9. doi: 10.1093/eurheartj/ehw336. https://doi.org/10.1093/eurheartj/ehw336

122. Volpe M. In memory of Professor John H. Laragh. High Blood Press Cardiovasc Prev. 2015;22(2):197. doi: 10.1007/s40292-015-0089-0. https://doi.org/10.1007/s40292-015-0089-0

123. Vonend O, Quack I, Rump LC. \[The role of aldosterone in hypertension\]. Wien Klin Wochenschr. 2010;122(3-4):65-74. doi: 10.1007/s00508-010-1313-5. (German). https://doi.org/10.1007/s00508-010-1313-5

124. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol. 2014;63(5):407-16. doi: 10.1016/j.jacc.2013.10.063. https://doi.org/10.1016/j.jacc.2013.10.063

125. Weiss S, Ellis LB. The rational treatment of arterial hypertension. JAMA. 2014;311(21):2238. doi: 10.1001/jama.2013.279537. https://doi.org/10.1001/jama.2013.279537

126. White PD. Heart in Hypertension Since the Days of Richard Bright. Can Med Assoc J. 1946;54(2):129-36.

127. White WB. Module 1: Historical review of evidence-based treatment of hypertension. J Fam Pract. 2012;61(8 Suppl):S5-14; quiz S27.

128. Widimský J. \[History of the treatment of essential hypertension–part II\]. Vnitr Lek. 2002;48(2):161-70. (Czech).

129. Widimský J. \[History of treatment of essential hypertension–part I\]. Vnitr Lek. 2002;48(1):62-70. (Czech).

130. Wofford JL. History of fixed-dose combination therapy for hypertension. Arch Intern Med. 1997;157(9):1044. https://doi.org/10.1001/archinte.1997.00440300166021

131. Zanchetti A. Platt versus Pickering: an episode in recent medical history. By J. D. Swales, editor. An essay review. Med Hist. 1986;30(1):94-6. doi: 10.1017/s0025727300045075. https://doi.org/10.1017/S0025727300045075

132. Zanchetti A. The basic importance of the physiological approach in clinical medicine: the experience in the area of hypertension. Arch Ital Biol. 2005;143(2):97-102.

133. Zhao Z, Wang H, Jessup JA, et al. Role of estrogen in diastolic dysfunction. Am J Physiol Heart Circ Physiol. 2014;306(5):628-40. https://doi.org/10.1152/ajpheart.00859.2013